The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Walgreens issued $750 million in senior unsecured notes at 8.125%, refinancing 3.800% notes due in 2024, leading to a $32.4 million increase in annual interest costs. Walgreens sold its remaining Cencora shares for $1.1 billion, with a potential $55 million annual interest expense savings, reducing its ownership in Cencora from 12% to 10%. The $750 million raised will primarily reduce Walgreens' existing debt, signaling confidence in handling higher debt servicing costs. The funds will also be allocated for potential growth investments.
Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.